You just read:

NGM Bio Initiates Phase 1 Clinical Trial of NGM313, a Proprietary Antibody with the Potential to Treat Type 2 Diabetes, Obesity and NASH

News provided by

NGM Biopharmaceuticals, Inc.

08 Jun, 2016, 09:00 ET